A first-half milestone

Shield Therapeutics (LSE:STX) reported a small operating profit for the first six months of 2026, compared with a sizeable loss a year earlier. The question is how the iron deficiency specialist achieved this, given that sales of its main product in the US grew only modestly, and how sustainable the improvement may be as it takes over full control of that market.

The company and its product

Shield Therapeutics is an AIM-quoted pharmaceutical company whose lead product, ferric maltol, is sold as ACCRUFeR in the US and through partners elsewhere. It is an oral treatment for iron deficiency. The US is its most important market, while licensing partners such as Norgine in Europe and the UK, ASK Pharm in China and KYE Pharmaceuticals in Canada pay milestones and royalties. Further launches through partners in Japan and Korea are targeted for 2027.

The interim results

On 20 August 2026, Shield reported total Revenue of US$30.4 million for the six months to 30 June 2026, up 42% from US$21.4 million. US ACCRUFeR revenue rose 5% to US$20.1 million. The bigger change came from outside the US: milestone and Royalty income totalled US$10.3 million, compared with US$2.2 million, including a US$7.9 million development milestone from ASK Pharm and US$2.1 million of royalties from Norgine.

As a result, the company recorded an operating profit of US$0.2 million, against an operating loss of US$5.8 million a year earlier, and the loss after tax narrowed to US$2.3 million from US$9.5 million. Gross Margin was 59.7%, on Gross Profit of US$18.1 million. The figures suggest that without the US$7.9 million ASK Pharm milestone, the group would have remained loss-making at the operating level.

Underlying US Demand grew faster than revenue. Prescriptions rose 21% to about 102,000, but the average net selling price fell to US$199 from US$214. Chief executive Anders Lundstrom said the sales force's adaptability was "encouraging given how quickly we pivoted to commercially insured patients" following Medicaid changes in New York.

Taking control in the US

On 27 August 2026, Shield announced that it would take full commercial control of ACCRUFeR in the US from Viatris, ending a co-commercialisation arrangement agreed in 2022. There is no upfront payment; instead, Shield will pay royalties on US net sales, rising from the high single digits in early years to the mid-teens over five years. Closing was expected on 30 September 2026. Shield said it would gain direct ownership of pricing, market access, promotion and the US sales force, and retain all gross profit from US sales before royalties. The company described the deal as "immediately accretive", and Mr Lundstrom said it would "significantly enhance the Economics of the business".

Balance sheet and risks

Cash fell to US$8.3 million at 30 June from US$11.6 million at the end of 2025. The company had drawn US$24.9 million of a US$25 million Facility from Runway Growth Capital, which matures in September 2028, with principal repayments starting in the third quarter of 2027. That combination of modest cash and approaching repayments is a key point to monitor.

The half-year profit relied heavily on a one-off milestone, so it may not recur in every period. Falling net prices could offset prescription growth, and payer decisions, such as the New York Medicaid change, can shift demand quickly. Running US sales alone also brings considerably more cost and execution responsibility for Shield.

Conclusion

Shield reached a half-year operating profit mainly because international milestone and royalty income rose sharply, while US prescriptions grew but net pricing declined. The company says it remains on track for operating profitability in 2026, and expects full US control to improve margins. Its ability to sustain profits without large milestones, while servicing its debt, will be the next test.